KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBT (2017 - 2025)

Aquestive Therapeutics has reported EBT over the past 9 years, most recently at -$31.9 million for Q4 2025.

  • Quarterly results put EBT at -$31.9 million for Q4 2025, down 86.65% from a year ago — trailing twelve months through Dec 2025 was -$83.8 million (down 89.77% YoY), and the annual figure for FY2025 was -$83.8 million, down 89.77%.
  • EBT for Q4 2025 was -$31.9 million at Aquestive Therapeutics, down from -$15.4 million in the prior quarter.
  • Over the last five years, EBT for AQST hit a ceiling of $8.1 million in Q1 2023 and a floor of -$31.9 million in Q4 2025.
  • Median EBT over the past 5 years was -$13.0 million (2022), compared with a mean of -$13.0 million.
  • Biggest five-year swings in EBT: tumbled 429.86% in 2021 and later skyrocketed 161.03% in 2023.
  • Aquestive Therapeutics' EBT stood at -$28.9 million in 2021, then surged by 57.33% to -$12.4 million in 2022, then soared by 35.15% to -$8.0 million in 2023, then crashed by 113.1% to -$17.1 million in 2024, then crashed by 86.65% to -$31.9 million in 2025.
  • The last three reported values for EBT were -$31.9 million (Q4 2025), -$15.4 million (Q3 2025), and -$13.5 million (Q2 2025) per Business Quant data.